Get all premium features to the best stock analysis tool

Solventum to Participate in the 2026 KeyBanc Healthcare Forum

ST. PAUL, Minn., March 11, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a virtual fireside chat at the KeyBanc Healthcare Forum on Wednesday, Mar. 18, 2026, beginning at approximately 10:30 a.m.

Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

Reported sales decreased 3.7%; organic sales increased 3.5% Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidance ST. PAUL, Minn.

Solventum Completes Acquisition of Acera Surgical

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S. Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency ST. PAUL, Minn.

Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care Solventum™  Prevena™ Therapy is the only closed incision negative pressure therapy system with fully integrated linear and area dressings solely indicated for closed incisions that utilize ROCF technology ST. PAUL, Minn.